Lucas Rodriguez is a serial biotech entrepreneur, investor, advisor, and business development strategist with over 15 years of experience in life sciences. He is the founder and former CEO of CerSci Therapeutics, a non-opioid pain therapeutics company acquired by Acadia Pharmaceuticals in a transaction valued at up to $950 million. Currently, Lucas serves as Partner and Head of Investor Services at Alacrita Consulting, where he advises biotech startups and institutional investors on clinical strategy, licensing, and investment readiness.

Throughout his career, Lucas has helped build and support startups from inception through clinical development, fundraising, and successful exit. His experience spans therapeutic areas including CNS, oncology, inflammatory diseases, and rare disorders. He has raised and deployed capital across the startup ecosystem, worked with top-tier VC firms, and led strategic partnerships with pharma and academia.

Lucas holds a PhD and MS in Biomedical Engineering from the University of Texas at Dallas and a BS in Biology from Baylor University.